Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Alton of Liverpool on 2016-01-26.
To ask Her Majesty’s Government what assessment the Human Fertilisation and Embryology Authority (HFEA) has made of recent research suggesting that the eggs of older women can be rejuvenated through injections of mitochondria from other cells; what data collected from clinics the HFEA holds regarding the incidence of aneuploidy in oocytes over time, and what evidence it has received from (1) OvaScience, (2) Professor Simon Fishel, and (3) other sources, that mitochondrial defects are primarily responsible for age-related exponential increases in oocyte aneuploidy; what published randomised trials the HFEA has been made aware of regarding the Augment technique, and what assessment it has made of those trials; and what assessment the HFEA has made of the credibility of claims by OvaScience and those previously made by Clonaid, in the light of data available in peer-reviewed journals.
Lord Prior of Brampton
The Human Fertilisation and Embryology Authority (HFEA) advises that it does not hold data from clinics on the incidence of aneuploidy in oocytes over time, nor has it received evidence from OvaScience, Professor Simon Fishel or other sources that mitochondrial defects are primarily responsible for age-related increases in oocyte chromosomal aneuploidy.
The HFEA also advises that it has not been made aware of any published randomised trials regarding the Augment technique and has not made an assessment of the credibility of claims by OvaScience and those previously made by Clonaid, in the light of data available in peer-reviewed journals. It is currently considering whether techniques, which involve addition of autologous mitochondria to eggs, would be legal in the United Kingdom (under the framework of the Human Fertilisation and Embryology Act 1990, as amended). Part of this consideration involves considering the claims made for Augment by Ovascience.
The HFEA has not received any formal applications for clinical use of the Augment technique, and has not made an assessment of the ruling by the US Food and Drugs Administration to which the Noble Lord refers.
